Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Plos One|October 21, 2014
Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysisRinat Yerushalmi, Hadar Goldvaser, Aaron Sulkes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2015
Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast CarcinomaMinh Nguyen, Shuichi Miyakawa, Junichi Kato, et al.
Familial Cancer|July 10, 2026
Breast cancer phenotypes in carriers of pathogenic POT1 variantsTal Hadar, Aasem Abu Shtaya, Rinat Bernstein-Molho, et al.
Breast Cancer Research and Treatment|October 10, 2020
Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcomeMatan Ben-Zion Berliner, Rinat Yerushalmi, Inbar Lavie, et al.
The Israel Medical Association Journal : IMAJ|May 5, 2017
A Dedicated Follow-Up Clinic for BRCA Mutation CarriersRinat Yerushalmi, Shulamith Rizel, Dalia Zoref, et al.
BMC Cancer|July 23, 2014
Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort studyDavid Margel, Ofer Benjaminov, Rachel Ozalvo, et al.
Breast Cancer Research and Treatment|March 27, 2021
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center studyDaniel Reinhorn, Iryna Kuchuk, Tzippy Shochat, et al.
Oncotarget|October 31, 2015
BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivoOrit Uziel, Rinat Yerushalmi, Lital Zuriano, et al.
The Lancet. Oncology|May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trialTanja Fehm, Francesco Cottone, Kyle Dunton, et al.
Breast Cancer Research and Treatment|November 19, 2024
ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomesHadar Goldvaser, Rinat Yerushalmi, Raz Mutai, et al.
Pageof 10